Table 2.
International Prognostic Scoring System (IPSS), WHO and karyotype classification of patients with MDS
| Characteristics | Chelation-naïve (n = 123) | Prior chelation (n = 44) |
|---|---|---|
| IPSS, n (%) | ||
| Low | 26 (21.1) | 14 (31.8) |
| Intermediate-1 | 39 (31.7) | 16 (13.0) |
| Intermediate-2 | 14 (11.4) | 2 (4.5) |
| High | 4 (3.3) | 0 |
| Missing | 40 (32.5) | 12 (27.3) |
| Karyotype, n (%) | ||
| Good | 45 (36.6) | 23 (52.3) |
| Intermediate | 24 (19.5) | 2 (4.5) |
| Poor | 4 (3.3) | 0 |
| Missing | 50 (40.7) | 19 (43.2) |
| WHO, n (%) | ||
| RA | 22 (17.9) | 17 (38.6) |
| RARS | 30 (24.4) | 10 (22.7) |
| RCMD | 10 (8.1) | 2 (4.5) |
| RCMD-RS | 0 | 2 (4.5) |
| RAEB-1 | 12 (9.8) | 2 (4.5) |
| RAEB-2 | 8 (6.5) | 1 (2.3) |
| MDS-U | 5 (4.1) | 1 (2.3) |
| Del (5q) syndrome | 13 (10.6) | 4 (9.1) |
| Missing | 23 (18.7) | 5 (11.4) |
WHO, World Health Organization; RA, refractory anaemia; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD and ringed sideroblasts; RAEB, refractory anaemia with excess blasts; MDS-U, unclassified myelodysplastic syndromes.